Company intelligence / Profile preview

MetriTrack

Ownership: Private
Development stage: Other

Overview

MetriTrack’s FDA-cleared BVN™ devices provide automated, standardized breast ultrasound mapping to improve early detection of breast cancer—especially in women with dense breasts. The technology enables precise lesion localization and reproducibility for diagnostic and treatment workflows. Clinical results highlight improved detection rates when used as a supplement to mammography.

Therapeutic areas: Women's HealthOncology
Modalities: Device
Industry: Medical Imaging

Partnerships

SST Group Inc. (collaboration to bring the BVN G‑2000 solution to imaging clinics across the Midwest)

Beyond the preview

Go deeper on MetriTrack.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MetriTrack.

Explore the full profile